This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Hexalen

Eisai Co., Ltd.

Drug Names(s): altretamine

Description: The active ingredient of HEXALEN is altretamine, a synthetic cytoxic antineoplastic s-triazine derivative. The exact mechanism of action of altretamine is not known, but the drug appears to interfere with the synthesis of genetic material within cells, thereby inhibiting the growth of cancer cells. A number of theoretical possibilities have been studied. Structurally, HEXALEN resembles thealkylating agent triethylenemelamine, yet in vitro tests for alkylating activity of HEXALEN and its metabolites have been negative. Metabolism of altretamine is a requirement forcytotoxicity. Synthetic monohydroxymethylmelamines, and products of altretamine metabolism, in vitro and invivo, can form covalent adducts with tissue macromolecules including DNA, but the relevance of these reactions to antitumor activity is unknown.

Deal Structure: Hexalen was originally developed by MGI Pharma.

In December 2007, Eisai and MGI Pharma announced that they entered into a definitive merger agreement under which Eisai would acquire all of the outstanding shares of MGI Pharma for US$41.00 per share in an all cash transaction, for a total consideration of approximately $3.9 billion.


Hexalen News

Pink Sheet U.S. Bioscience

Pink Sheet U.S. Bioscience

Pink Sheet MGI Pharma Hexalen


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug